- Home
- PHGE vs COCP Comparison
PHGE vs COCP Comparison
Compare PHGE & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- COCP
- Stock Information
- Founded
- PHGE 2015
- COCP 2006
- Country
- PHGE Israel
- COCP United States
- Employees
- PHGE N/A
- COCP N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- PHGE Health Care
- COCP Health Care
- Exchange
- PHGE Nasdaq
- COCP Nasdaq
- Market Cap
- PHGE 15.5M
- COCP 15.4M
- IPO Year
- PHGE N/A
- COCP N/A
- Fundamental
- Price
- PHGE $0.58
- COCP $1.14
- Analyst Decision
- PHGE Strong Buy
- COCP Strong Buy
- Analyst Count
- PHGE 1
- COCP 1
- Target Price
- PHGE $15.00
- COCP $6.00
- AVG Volume (30 Days)
- PHGE 397.5K
- COCP 190.8K
- Earning Date
- PHGE 11-13-2025
- COCP 11-12-2025
- Dividend Yield
- PHGE N/A
- COCP N/A
- EPS Growth
- PHGE N/A
- COCP N/A
- EPS
- PHGE N/A
- COCP N/A
- Revenue
- PHGE N/A
- COCP N/A
- Revenue This Year
- PHGE N/A
- COCP N/A
- Revenue Next Year
- PHGE N/A
- COCP N/A
- P/E Ratio
- PHGE N/A
- COCP N/A
- Revenue Growth
- PHGE N/A
- COCP N/A
- 52 Week Low
- PHGE $0.34
- COCP $1.01
- 52 Week High
- PHGE $1.16
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- PHGE 53.87
- COCP 44.29
- Support Level
- PHGE $0.55
- COCP $1.01
- Resistance Level
- PHGE $0.63
- COCP $1.12
- Average True Range (ATR)
- PHGE 0.05
- COCP 0.07
- MACD
- PHGE -0.00
- COCP 0.01
- Stochastic Oscillator
- PHGE 35.85
- COCP 47.41
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).